Evaluation of FES (16α-[18F]-fluoro-17β-estradiol) PET for (re)staging of patients with clinical (locally) advanced or locoregional recurrent estrogen receptor positive breast cancer

R. Iqbal, C. Mo, M. C. F. Cysouw, A. W. J. M. Glaudemans, G. A. P. Hospers, C. P. Schroder, C. C. M. Venema, C. W. Menke-van der Houven van Oordt

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)S88
JournalEuropean Journal of Cancer
Publication statusPublished - 1 Oct 2020

Cite this